TD Cowen Initiates Coverage on Teva With Buy Rating, Cites Innovative Pipeline

American investment bank TD Cowen has launched its analyst coverage of Teva Pharmaceutical Industries, initiating with a "buy" recommendation. The firm cited Teva's dual business model, which combines a stable revenue stream from its generic and biosimilar drugs with a growing pipeline of innovative products, as the key driver for its positive outlook.

Under CEO Richard Francis, Teva has shifted its strategy to prioritize original drugs, such as Austedo for movement disorders, alongside others like Ajovy and Uzedy. This focus on innovative treatments is supported by the substantial cash flow generated from its large generics business, which funds the company's transition.

The positive recommendation follows a strong year for Teva's stock. After struggling with significant debt and numerous lawsuits, the company experienced a turnaround in 2026. This included regaining an investment-grade credit rating from S&P, which allowed Teva to raise over $1 billion in debt on more favorable terms, thereby reducing its financing burden.

Furthermore, Teva has improved its standing with U.S. regulators, being one of nine companies to sign an agreement with the Trump administration regarding drug pricing. This move has lessened some of the uncertainty that has plagued the pharmaceutical sector. These developments have been reflected in Teva's stock performance, which has seen a significant rise since the beginning of the year, making it a notable performer on both the Tel Aviv and Wall Street exchanges.

The initiation of coverage by TD Cowen reinforces the market's perception of Teva as a growth company, moving beyond its previous image as a leveraged generics manufacturer focused on survival. The primary question moving forward will be the extent to which Teva's innovative pipeline can continue to expand as competition in the generics market intensifies.